(SRDX) REPORT OVERVIEW Surmodics Recent Financial Performance For the. Ero does not, by its reference above or distribution imply its endorsement of, or concurrence with, such information, conclusions, or recommendations. Twitter (SRDX) All News Analyst Coverage Analyst Ratings News Coverage News General Contracts Dividend Summaries Dividend Calendar Events FDA M&A Offerings Stock Split Media Buybacks Insider. New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan. This suggests a possible upside of 61.2 from the stock's current price. According to, Petusky is a 4-star analyst with an average return of 7.7 and a 47.9 success rate. The companys shares closed last Thursday at 40.68. On average, they expect Surmodics' share price to reach 58.00 in the next year. Barrington analyst Michael Petusky reiterated a Buy rating on SurModics (SRDX Research Report) today and set a price target of 70.00. Their SRDX stock forecasts range from 58.00 to 58.00. Latest news headlines for Surmodics Inc with market analysis and analyst commentary. Please note that any opinions, estimates, or forecasts regarding Ero’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Ero or its management. 1 equities research analysts have issued 12-month price targets for Surmodics' shares. Ero is followed by the research analysts listed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |